title: Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies.
abstract: Locoregional spread of abdominopelvic malignant tumors frequently results in peritoneal carcinomatosis (PC). The prognosis of PC patients treated by conventional systemic chemotherapy is poor, with a median survival of < 6 mo. However, over the past three decades, an integrated treatment strategy of cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed by the pioneering oncologists, with proved efficacy and safety in selected patients. Supported by several lines of clinical evidence from phases I, II and III clinical trials, CRS + HIPEC has been regarded as the standard treatment for selected patients with PC in many established cancer centers worldwide. In China, an expert consensus on CRS + HIPEC has been reached by the leading surgical and medical oncologists, under the framework of the China Anti-Cancer Association. This expert consensus has summarized the progress in PC clinical studies and systematically evaluated the CRS + HIPEC procedures in China as well as across the world, so as to lay the foundation for formulating PC treatment guidelines specific to the national conditions of China.
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Yan
authors: Y
authors: Li
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Yun-Feng
authors: YF
authors: Zhou
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Han
authors: H
authors: Liang
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Hua-Qing
authors: HQ
authors: Wang
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Ji-Hui
authors: JH
authors: Hao
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Zheng-Gang
authors: ZG
authors: Zhu
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: De-Seng
authors: DS
authors: Wan
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Lun-Xiu
authors: LX
authors: Qin
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Shu-Zhong
authors: SZ
authors: Cui
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Jia-Fu
authors: JF
authors: Ji
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Hui-Mian
authors: HM
authors: Xu
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Shao-Zhong
authors: SZ
authors: Wei
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Hong-Bin
authors: HB
authors: Xu
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Tao
authors: T
authors: Suo
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Shu-Jun
authors: SJ
authors: Yang
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Cong-Hua
authors: CH
authors: Xie
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Xiao-Jun
authors: XJ
authors: Yang
authors: Yan Li, Department of Peritoneal Cancer Surgery, Cancer Center of Beijing Shijitan Hospital Affiliated to the Capital Medical University, Beijing 100038, China.
authors: Guo-Liang
authors: GL
authors: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D010534:Peritoneal Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents
keywords: Colorectal cancer; Cytoreductive surgery; Expert consensus; Gastric cancer; Intraperitoneal hyperthermic chemotherapy; Ovarian cancer; Peritoneal carcinomatosis; Peritoneal mesothelioma; Peritoneal sarcoma; Pseudomyxoma Peritonei